帕博利珠单抗联合奥拉帕利治疗转移性去势抵抗性前列腺癌:1b/2期KEYNOTE-365研究A队列长期结果
KEYNOTE-365研究A队列纳入104例分子未选择、多西他赛经治且筛查前6个月内进展的转移性去势抵抗性前列腺癌(mCRPC)患者,评估帕博利珠单抗联合奥拉帕利的疗效与安全性。确认PSA缓解率15%,可测量病灶客观缓解率(ORR)8.5%,中位影像学无进展生存期(rPFS)4.5个月,中位总生存期(OS)14个月。安全性特征与单药一致,3-5级治疗相关不良事件发生率为48%。
要点
- 确认PSA缓解率15%,可测量病灶确认ORR为8.5%(5例部分缓解)。
- 中位rPFS为4.5个月(95%CI 4.0-6.5),中位OS为14个月(95%CI 10.4-18.2)。
- 3-5级治疗相关不良事件发生率为48%,6例死亡中2例归因于治疗。
核心结论
- 帕博利珠单抗联合奥拉帕利的安全性特征与各单药一致,并在分子未选择、多西他赛经治的mCRPC患者中显示出抗肿瘤活性。
研究设计与样本
- 1b/2期KEYNOTE-365研究A队列纳入104例分子未选择、多西他赛经治且筛查前6个月内进展的mCRPC患者,其中102例接受治疗。
- 干预为帕博利珠单抗200 mg静脉注射每3周一次联合奥拉帕利400 mg胶囊或300 mg片剂口服每日两次。
- 主要终点为安全性、确认PSA缓解率和盲态独立中心审查按RECIST 1.1评估的ORR;次要终点包括rPFS和OS。
主要发现
- 确认PSA缓解率为15%;可测量病灶患者的确认ORR为8.5%(5例部分缓解)。
- 中位rPFS为4.5个月(95%CI 4.0-6.5),中位OS为14个月(95%CI 10.4-18.2)。
- 临床活性在PD-L1阳性和同源重组修复突变亚组中一致。
- 治疗相关不良事件发生于93例(91%)患者,3-5级治疗相关不良事件发生于49例(48%)患者。
- 6例死亡(5.9%)由不良事件导致,其中2例(心肌梗死和原因不明)归因于治疗。
局限性
- 研究局限性包括单臂设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pembrolizumab and olaparib have shown single-agent activity in patients with previously treated metastatic castration-resistant prostate cancer (mCRPC). OBJECTIVE: To evaluate the efficacy and safety of pembrolizumab plus olaparib in mCRPC. DESIGN, SETTING, AND PARTICIPANTS: Cohort A of the phase 1b/2 KEYNOTE-365 study enrolled patients with molecularly unselected, docetaxel-pretreated mCRPC whose disease progressed within 6 mo of screening. INTERVENTION: Pembrolizumab 200 mg intravenously every 3 wk plus olaparib 400-mg capsule or 300-mg tablet orally twice daily. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoints were safety, confirmed prostate-specific antigen (PSA) response rate, and objective response rate (ORR) as per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, by blinded independent central review. The secondary endpoints included radiographic progression-free survival (rPFS) and overall survival (OS). RESULTS AND LIMITATIONS: Of 104 enrolled patients, 102 were treated. The median age was 70 yr (interquartile range [IQR], 65-76), and 59 patients (58%) had measurable disease as per RECIST v1.1. The median time from the first dose to database cutoff was 24 mo (IQR, 22-47). The confirmed PSA response rate was 15%. The confirmed ORR was 8.5% (five partial responses) for patients with measurable disease. The median rPFS was 4.5 mo (95% confidence interval [CI], 4.0-6.5) and median OS was 14 mo (95% CI, 10.4-18.2). Clinical activity was consistent across the programmed death ligand 1 (PD-L1)-positive and homologous recombination repair mutation subgroups. Treatment-related adverse events (TRAEs) occurred in 93 patients (91%). Grade 3-5 TRAEs occurred in 49 patients (48%). Six deaths (5.9%) were due to adverse events; two (myocardial infarction and unknown cause) were attributed to treatment. Limitations of the study include the single-arm design. CONCLUSIONS: Pembrolizumab plus olaparib had a safety profile consistent with the profiles of the individual agents and demonstrated antitumor activity in previously treated patients with molecularly unselected, docetaxel-pretreated mCRPC. PATIENT SUMMARY: Pembrolizumab plus olaparib showed antitumor activity and expected safety in patients with metastatic castration-resistant prostate cancer.
引用
- Yu EY, Piulats JM, Gravis G, et al. Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study. Eur Urol. 2022. PMID: 36055895. doi:10.1016/j.eururo.2022.08.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。